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[57] ABSTRACT
Thepresent invention involves a method for detecting
the unique aberrant genetranscripts of a targeted cellu-
lar genomic abnormality in a tissue sample. This method
comprises a series of steps. Initially, total cellular RNA
or m-RNAis preferred from the tissue sample to be
analyzed for the presence of a genomic abnormality.
The total cellular RNA or m-RNAis then mixed with
at least one synthetic DNA oligonucleotide comple-
mentary to the unique RNA sequenceof the targeted
cellular genomic abnormality being detected. The mix-
ing is under conditions facilitating formation of double
stranded DNA-RNA heteroduplexes when a strand of
synthetic DNAoligonucleotide is complementary to an
RNAstrand obtained from the tissue sample. The con-
ditions are those such as time, salt concentration, tem-
perature and pH 10. The synthetic DNA oligonucleo-
tide is preferably about several hundred nucleotides in
length, more preferably about 60 to about 150 nucleo-
tides in length.
In a most preferred embodiment, the method of the
present invention may be applied to the detection of
residualcells of chronic myelogenous leukemia withits
characteristic Philadelphia chromosome(Ph!). Forthis
situation, the first primer is primer ber Ex III(+) or ber
Ex II (+), most preferably a mixture of primer bcr Ex
II (+) and ber Ex II (++). In certain instances the sec-
ond primer mayalso be a mixture of twodifferent prim-
ers, particularly where there is a variable breakpoint in
the second chromosomal memberofthe translocation
characteristic of a neoplasm. Where residual cells of
chronic myelogenous leukemia are being detected, the
second primeris most preferably primer abl (—).
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DETECTION OF GENOMIC ABNORMALITIES
WITH UNIQUE ABERRANT GENE TRANSCRIPTS
BACKGROUNDOF THE INVENTION
Thepresentinvention involves using a new technique
for the detection of genomic abnormalities. Such detec-
tion may proveparticularly useful to predict recurrence
of cancer, or early detection of cancer.
High frequency of recurrence is one of the major
problems in cancer treatment. Relapse from clinically
undetectable residual disease is the most likely mecha-
nism (1). Detection of minimal disease is extremely
difficult since tumor specific markers are not readily
available. Molecular technology has provided a means
to demonstrate residual disease by identifying clonal
gene rearrangement patterns that may present, for ex-
ample, in malignant hematopoietic cells (2). Southern
blot hybridization may detect neoplastic cells at levels
as low as 1% ofthe total numberofcells (3). However,
one of the major drawbacks in using such traditional
methods is that it is difficult to be certain that faint
nongermline bands indeed represent clonal rearrange-
ments representative of neoplastic cells. Furthermore,
no rearranged bands can usually be detected by tradi-
tional methods in cases in which the concentration of
neoplastic cells is below 1%. It is expected that such a
low concentration occurs frequently while patients are
in remission.
Saiki et al. have recently utilized a new technique,
sequence amplification by polymerase chain reaction
(PCR), to diagnose sickle cell anemia prenatally (4).
This technique is highly sensitive. It requires small
amounts ofDNA(less than | ug) and can amplify copies
of target DNA sequences exponentially.
Recently, the present inventor has utilized polymer-
ase chain reaction (PCR) technology to preferentially
amplify the hybrid DNA sequences of a chromosomal
translocation, t(14;18), characteristic of follicular lym-
phoma. This technique detected neoplastic cells carry-
ing the t(14;18) in a concentration ofless than 1:100,000
(5).
A major limitation of the PCR technique has been
thought to involve the ability to amplify only short
DNAsegments (e.g., several hundred base pairs). Such
amplification was feasible for the t(14;18) translocation
because the molecular breakpoints on both chromo-
somes occurred within a limited region (6-8). However,
this approach was notapplicable to chromosomal trans-
locations with more variable breakpoints, and also was
not feasible for amplification of RNA without major
modifications of the procedure. The present invention
relates to modification of the PCR techniqueso thatit
may detect the presence of minimal amounts of aberrant
gene transcripts from the neoplastic cells that carry a
chromosomal translocation with variable molecular
breakpoints. Neoplastic cells such as those bearing the
Philadelphia Ph! chromosome, for example, could then
be detected.
Ph! chromosome (t(9;22) (q34;qi1)), has been ob-
served in more than 90% of chronic myelogenousleu-
kemia (CML)cases (9,10). Even though the breakpoints
on chromosome 22ql! cluster within a small DNA
segment designated as bcr (11,12), the breakpoints on
chromosome 9q34 occur at variable positions up to
more than 100 kilobases (kb) 5’ to the second exon of the
c-abl oncogene (13,14). Despite the variability of the








ber/abl gene in CMLis transcribed into two types of
chimeric mRNA: one with abl exon II linked to ber
exon “2” (designated as L-6 junction) and the other one
with abl exon II linked to ber exon “3” (designated as
K-28 junction) (15). By means of RNase protection
analysis, the Ph!-positive K562 cell line has been shown
to have both types of mRNA (15). In a study of 21
Ph!-positive CMLpatients, one or both RNA junctions
were detected in 19 patients (16).
SUMMARYOF THE INVENTION
The present invention involves a method for detect-
ing the unique aberrant gene transcripts produced by a
targeted cellular genomic abnormality in a tissue sam-
ple. This method comprises a series of steps. Initially,
cellular RNAis extracted from the tissue sample to be
analyzed for the presence of a genomic abnormality.
The extracted RNA is then mixed with at least one
synthetic antisense DNA oligonucleotide complemen-
tary to the unique RNAsequencesofthe targeted cellu-
lar genomic abnormality being detected. The mixingis
under conditions facilitating formation of double
stranded DNA-RNAheteroduplexes when a strand of
synthetic DNA oligonucleotide is complementary to an
RNAstrand obtained from the tissue sample. The con-
ditions facilitating formation are those such as time,salt
concentration, temperature and pH. The synthetic
DNAoligonucleotide is preferably about several hun-
dred nucleotides in length, more preferably about 60 to
about 150 nucleotides in length.
When a chromosomic abnormality characterizing
residual ceils of chronic myelogenous leukemiais to be
detected, the preferred synthetic DNA oligonucleotide
comprises anti-L6 or anti-K28 and most preferably
comprises a mixture thereof. The mixture, with single
stranded polynucleotides and/or oligonucleotides and
DNA-RNAheteroduplexes, if any, is then treated with
a single-strand specific (S1) nuclease whereby single
stranded RNAandsingle stranded DNA but not double
stranded DNA-RNAheteroduplexes are hydrolyzed. A
preferred nuclease is S; nuclease, Mung bean nuclease
or RNase. The result of this nuclease digestion is that
only DNA and RNA which werein heterodupiexes
were saved from hydrolysis or digestion to nucleotides.
The nuclease is next deactivated and the nuclease-resist-
ant DNA-RNAheteroduplexes are then denatured to
single stranded DNA and RNA.
The protected single stranded DNAofthe denatured
mixture is then subjected to at least about 20 rounds of
polymerase chain reaction (PCR) to exponentially am-
plify targeted DNA sequences. Each round of PCR
involves at least one first primer complementary to a
portion of the 3’ end of the antisense synthetic DNA
oligonucleotide and at least one second primeridentical
to a portionofthe 5’ end of the synthetic DNAoligonu-
cleotide. The primers are preferably oligonucleotides of
between about 12 and about 20 nucleotides in length.
In a most preferred embodiment, the method of the
present invention may be applied to the detection of
residual cells of chronic myelogenous leukemia with its
characteristic Philadelphia chromosome(Ph!). Forthis
situation, the first primer is primer bcr Ex III (+) (de-
rived from the third exon of the ber region) or ber ExII
(+) (derived from the second exon of the ber region),
most preferably a mixture of primer ber Ex III (+) and
ber Ex II (+). In certain instances the second primer
mayalso be a mixture of twodifferent primers, particu-
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larly where there is a variable breakpoint in the second
chromosomal memberof the translocation characteris-
tic of a neoplasm. Whereresidual cells of chronic mye-
logenous leukemia are being detected, the second
primer is most preferably primer abl (—) derived from
the second exon of the C-abl gene.
Theprimersare preferably kept at a concentration of
about 1 micromolar (uM)in the above-described PCR
reaction. This concentration is an excess for the re-
peated rounds of amplification. The rounds of polymer-
ase chain reaction, when the tissue sample contained
m-RNA transcripts of the targeted cellular genomic
abnormality, resulted in exponential production of am-
plimers of unhydrolyzed antisense synthetic DNAolli-
gonucleotide and DNA oligonucleotides complemen-
tary thereto. The presence or absence of amplimers
comprising nucleotide sequences characteristic of the
unique aberrant gene transcripts of the targeted cellular
genomic abnormality or the complementary synthetic
DNAoligonucleotide is then established. Said presence
is detected only where complementary m-RNA from
the tissue sample has protected the synthetic antisense
DNA oligonucleotide from nuclease digestion. The
method of detecting the amplimers indicative of the
targeted genomic abnormality preferably involves elec-
trophoresis of the polymerase chain reaction amplimer
product and preparation of a Southern blot. In sum-
mary, the detecting step most preferably involves elec-
trophoretic separation of amplimers, transfer to a nylon
or nitrocellulose paper and exposureto a labelled oligo-
nucleotide probe having a nucleotide sequence charac-
teristic of the unique aberrant gene transcript of the
chromosomal abnormality or a genomic component
thereof.
As mentioned above, the present invention more
specifically involves a method for detecting residual
chronic myelogenous leukemia cells of a patient in a
state of clinical remission. Said cells are characterized
by the chromosomic abnormality Ph! chromosome.
This more specific method comprises an analogous
series of steps. The total cellular RNA or m-RNAis
initially prepared from blood cells of said patient. The
extracted total cellular RNA or m-RNAis then mixed
with at least one synthetic DNA oligonucleotide com-
plementary (antisense) to a characteristic portion of the
aberrant genetranscripts of the Ph! chromosome. This
mixing facilitates formation of double stranded DNA-
RNA heterodupiexes when DNA and RNA comple-
mentary strands are present. The mixtureis then treated
with single-strand specific nuclease (e.g., S; nuclease) to
hydrolyze single stranded RNA andsingle stranded
DNAbut not double stranded DNA-RNAheterodu-
plexes. The nuclease is then deactivated and the
heteroduplexes denatured to form single stranded DNA
and RNA.
The protected antisense DNA of the denatured mix-
ture is then subjected to at least about 20 rounds of
polymerase chain reaction with at least one first primer
complementary to a portion of the 3’ end of the an-
tisense synthetic DNA oligonucleotide and at least one
second primeridentical to a portion of the 5’ end of the
antisense synthetic DNA oligonucleotide. Such a poly-
merasechain reaction results in the exponential produc-
tion of amplimers of unhydrolyzed antisense synthetic
DNAoligonucleotide and DNAoligonucleotides com-
plementary thereto. Lastly, the presence of DNA am-
plimers comprising nucleotide sequences characteristic












phia chromosome or the complementary synthetic
DNAoligonucleotide is determined. Such presence is
detected only where complementary m-RNAfrom the
tissue sample has protected the synthetic antisense
DNAoligonucleotide from nuclease digestion. The’
presence of these amplimers are indicative of residual
cells of chronic myelogenous leukemia in the patient
and may guide further therapeutic decisions.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 showsthe sequences of primers and synthetic
antisense oligonucleotides used herein.
FIG. 2 schematically shows the combined method of
the present invention.
FIG. 3 shows a Southern blot analysis of amplimers
from PCR action upon DNAprotected from nuclease
digestion.
FIG. 3A compares PCR amplifications of anti-K28,
MSL-60 (a control random base sequence DNA) and
normal RNA subjected to various conditions of S; nu-
clease digestion. FIG. 3B shows the PCR amplification
of anti-K28 and MSL-60 compared with RNA from
Ph!-positive CMLpatients.
FIG. 4 shows nuclease protection analysis of chime-
ric ber/abl transcripts.
FIG. 5 shows a Southern blot analysis of genomic
DNAfrom patient blood samples.
DESCRIPTION OF THE PREFERRED
EMBODIMENT
The following examples are presented to describe
preferred embodiments and utilities of the present in-
vention and are not meanttolimit the present invention
unless otherwise stated in the claims appended hereto.
Thepresent invention involves a method for detect-
ing chromosomal abnormalities by virtue of an analysis
dependent upon RNAtranscripts of specific chromo-
somal abnormalities in question. At least one DNA
oligonucleotide having a nucleotide sequence comple-
mentaryto the characteristic portion of the unique aber-
rant gene transcripts of the chromosomal abnormality
in question is synthesized. A further aspect of the pres-
ent invention involves single-strand-specific nuclease-
induced hydrolysis of single chain synthetic polynu-
cleotides or oligonucleotides. The nuclease to be used is
one such as S; nuclease which is unable to hydrolyze
DNA-RNA heteroduplexes under the chosen condi-
tions. The synthetic oligonucleotide is protected from
hydrolysis by the nuclease when it is present as a
heteroduplex with messenger RNA having a comple-
mentary nucleotide sequence. Thus, cellular extracts
from, for example, a patient harboring cells with a par-
ticular chromosomal abnormality should have the char-
acteristically transcribed messenger RNA. Extracts of
the RNA would protect a complementary (antisense)
synthetic oligonucleotide from nuclease digestion while
oligonucleotides not protected by such heteroduplex
formation would be digested to nucleotides.
In a subsequent step of the present invention, the
technique of polymerase chain reaction (PCR) is ap-
plied. The PCR technique is applied, by virtue of care-
fully selected primers, to exponentially amplify undi-
gested synthetic oligonucleotides. Thus, there will only
be a synthetic oligonucleotide to amplify exponentially
when there has been complementary messenger RNA
to protect the oligonucleotide from nuclease digestion.
Thepresent invention and the method described herein
are applicable to the detection of any chromosomal
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abnormality, particularily where that chromosomal ab-
normality has known transcription products.
The technique of the present invention has been spe-
cifically applied, by way of an example,to thesituation
found with chronic myelogenous leukemia, said leuke-
mia being characterized by the Philadelphia chromo-
some. The Philadelphia chromosome (Ph!) in chronic
myelogenous leukemia (CML) involves reciprocal
translocation of the bcr gene and the c-abl oncogene.
The fused ber/abl geneis transcribed into two types of
chimeric mRNA. By combining nuclease protection
reaction and polymerase chain reaction technology,
sequences representative of the chimeric bcr/abl tran-
scripts were amplified exponentially. Only 5 ug oftotal
cellular RNA was needed and the chimeric bcr/abl
message could be detected at a dilution of 1:100,000 as
determined by mixing studies using the RNA from the
Ph!-positive K562 cell line. Residual chimeric ber/abl
transcripts were also detectable in remission samples
from two Ph!-positive CMLpatients. This technique
should allow identifications of a subpopulation of Ph!-
- positive CML patients, who, in remission, are yet at
high risks of relapse.
Thetotal cellular RNA from the K562 cell line was
used to establish the feasibility of combining single-
strand-specific nuclease protection and PCR to amplify
sequences representative of the chimeric bcr/abl tran-
scripts characteristic of CML. Two synthetic DNA
oligonucleotides (oligomers) of 99 bases were prepared:
one with a sequenceantisense to the L-6 junction (anti-
L6) and the other one with a sequence antisense to the
K-28 junction (anti-K28), as designated in FIG. 1A (11,
15). FIG. 1 shows the sequences of the primers and
synthetic antisense oligonucleotides used in practice of
this embodiment of the present invention. FIG. 1(A).
The sequences of the anti-K28 and anti-L6 oligomers
are antisense to the K28 and the L6 mRNAjunctions
respectively (15). Both antisense oligomers are 99 bases
in which the 50 bases on the 5’ side are derived from the
second exon of the abl gene and the 49 bases on the 3’
side (underlined) are derived from the second exon (in
case of anti-L6) or the third exon(in case of anti-K28)of
the ber region.
Also shown in FIG. 1(A) are the sequences and loca-
tions of the corresponding primersrelative to the an-
tisense oligomers: Primers ber Ex II (+) and abl (—) for
anti-L6; and Primers ber Ex III (+) and abl (—) for
anti-K28. The complementary sequences are indicated
by vertical dots and the identical sequences are indi-
cated by vertical lines. The predicted sequences ampli-
fied are 80 bp in size. FIG. 1(B) shows the sequence of
the MSL-60 oligomer along with its corresponding
primers [18q21(+) and Jx(—)}] which have been de-
scribed (5). Except that the 12 bases of the 3’ end are
complementary to the 18q21(+) primer(vertical dots)
and the 12 bases ofthe 5’ end areidentical to the Jx{(—)
primer(vertical lines), the sequence of MSL-60 is ran-
domly selected. Theoretically, it is not. fully comple-
mentary to any RNA sequence.
The methods of the present invention involve use of
the single-strand-specific nuclease which preferentially
cleaves single stranded DNA or RNA butnot the dou-
ble stranded DNA-RNA heteroduplex under selected
conditions (17,18). In the presence of chimeric bcr/abi
transcripts, the full length antisense oligomers (either
anti-L6 and/or anti-K28) would be protected from di-










a half length of the antisense oligomers would be pro-
tected in samples containing the ber or abl transcripts.
FIG. 2 shows a schematic illustration of the com-
bined method of single-strand-specific nuclease protec-
tion and PCR using the anti-K28 oligomer as an exam-
ple. The anti-K28 oligomer wasfirst allowed to hybrid-
ize with an RNA sample which contained the chimeric
bcr/abl transcripts, the ber transcript, the abl transcript
and other mRNAs. The anti-K28 oligomer would be
matchedin full length with the chimeric ber/abl tran-
script with K28 junction, but only matched in half
length with the ber transcript or the abl transcript. The
single-strand-specific nuclease was then added to cleave
all the single stranded and mismatched sequences. The
nuclease resistant DNA-RNA heteroduplexes were
then denatured and subjected to PCR byusing primers
ber Ex III (+) and abl (—). In cases where only the
sequence complementary to the abl region was pro-
tected, no new copies of the abl sequence (40 mer)
could be synthesized because primer abl (—) had a
sequenceidentical to the protected DNA oligomer(the
right panel). In cases where the sequence complemen-
tary to the ber region wasprotected, only 20 new copies
of the ber sequence (40 mer) could be madeat the end
of 20 cycles of PCR (the middle panel). Only when the
chimeric ber/abl transcript was present and the full
length antisense oligomer was protected, new copies of
sequence equivalent to the chimeric mRNA junction
could be exponentially amplified (the left panel).
Following digestion of the single-strand-specific nu-
clease, the corresponding primers [ber Ex II (+), ber
ExIII (+) and abl (—) (FIG. 1A)] were used and PCR
performed to amplify the nuclease-resistant hybrids.
The sequences could be amplified only in cases where
the chimeric ber/abl RNA transcripts were present and
the full length antisense oligomers were protected
(FIG.2) from hydrolysis. The amplified sequences (am-
plimers) were predicted to be 80 base pairs (bp) in
length (FIG. 1A). Another DNA oligomerof 60 bases
with randomly selected sequence (MSL-60) and the
corresponding primers [18q21(+) and JH(—)] were
used in the same reaction as an internal control (FIG.
1B). Since MSL-60 contained a unique sequence that
would not be fully matched with any RNA sequence,it
should be completely digested by the singlestrand-
specific nuclease, such as S; nuclease. Amplification and
detection of the 60 mers would have indicated incom-
plete digestion of the mismatched oligomers by nucle-
ase.
FIG. 3 showsa Southern blot analysis of the sequen-
ces that were protected from S; nuclease digestion and
amplified by PCR. The S; nuclease protection reaction
contained 5 ug of total cellular RNA samples, | ng of
anti-L6, 1 ng of anti-K28 and 1 ng of MSL-60in 20 ul of
hybridization buffer (40 mM PIPES pH 6.4, 1 mM
EDTA, 0.4 M NaCl, 80% formamide). Hybridization
was performed at 50° C. overnight. The samples were
then diluted with 180 ul of S; nuclease reaction buffer
(280 mM NaCl, 50 mM sodium acetate pH 4.6, 4.5 mM
zinc sulfate) containing various units of S| nuclease and
incubated at 37°C. for | hour. The reaction was termi-
nated by adding 0.2 M EDTA followed by phenol/-
chloroform extraction. The S; nuclease resistant hy-
brids were then resuspended in a buffer containing 10
mM Tris pH 7.5, 50 mM NaCl, 10 mM MgCl, 1.5 mM
each of dNTP, 1 uM ber Ex II (+), 1 uM ber ExIII
(+), | uM abl (—), 1 uM 18q21 (+), 1 uM Jy(—). PCR
was then performed for 25-40 cycles as described in
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U.S. Pat. No. 4,683,202 July 28, 1987 (Mullis) at column
17, lines 50-65 and at column 18, lines 1-5 and incorpo-
rated by reference thereto. The PCR amplified samples
(5 ul) were then loaded to a 3% agarose minigel and
subjected to electrophoresis (50 V) for 4 hours. The gel
was then denatured, neutralized and transferred to a
nylon filter. The filter was prehybridized as described
(4) and then hybridized with a mixture of 32P-labelled
anti-K26, anti-L6, MSL-60 (specific activity >5 uCi/p-
mol) at 42° C. for 18 hours. The washing condition and
autoradiography werecarried out as described (4).
FIG. 3(A) shows PCR amplification of 25 pg of anti-
K28 (Lane 1) and MSL-60 (Lane 2) without prior S;
nuclease treatment for 10 cycles. The amplified seg-
ments were approximately 80 bp (Lane 1) and 60 bp
(Lane 2) as predicted. Lanes 3 and 4: the normal RNA
inadequately treated with S; nuclease and then PCR
amplified for 20 and 25 cycles respectively. Two bands
that were 80 bp and 60 bpin size were detected in both
lanes, indicating false positivity. Lanes 5 and 7: the
normal RNAtreated with increasing concentrations of
S; nuclease and then PCR amplified for 25 cycles. Nei-
ther the 80 bp band nor the 60 bp band wasdetected.
The faint shadow in Lane 7 appeared to be a back-
ground shadowin ouroriginal autoradiograph. Lanes 6
and 8: the RNA samples from the K.562 cell line treated
with S; nuclease and PCR amplified for 25 cycles. The
concentrations of S; nuclease used in Lanes 6 and 8
were the same as those used in Lanes 5 and 7 respec-
tively. In both instances, the 80 bp band representative
of the chimeric ber/abl transcripts was clearly demon-
strated and the “internal control” 60 mer was absent.
FIG. 3(B) shows 25 pg of anti-K28 (Lane 1) and
MSL-60 (Lane 2) without prior S; nuclease treatment
PCR amplified for 15 cycles. Lanes 3 and 4: a sample
containing 0.05 ng of total RNA from the K562 cell line
and 5 ug of the normal RNA subjected to S; nuclease
digestion followed by PCR amplification for 32 and 40
cycles respectively. A strong and convincing band of 80
bp was detected in both lanes. Lanes 5 (patient A) and
6 (patient B): the total RNAs of the remission blood
samples obtained from two Ph!-positive CML patients
treated with S; nuclease and PCR amplified for 35 cy-
cles. A band of 80 bp representative of the chimeric
bcr/abl transcripts was clearly demonstrated in both.
The molecular weight markers were labelled ontheleft
side of the figures.
As shownin FIG.3A,lanes 3 and 4, both the 80 mers
and 60 mers were amplified in the RNA sample from a
normal lymph node (referred to hereafter as normal
RNA), that was inadequately treated with Snuclease.
When adequate amounts of S; nuclease were added to
the normal RNA samples, neither the antisense oligo-
mersnorthe “internal control”oligomer wasprotected.
These unprotected oligomers were not amplified (FIG.
3A, Lanes 5 and 7). In contrast, only the antisense oligo-
mers were protected by RNA samples of the K562cell
line when adequately treated with S; nuclease and sub-
sequently amplified (FIG. 3A, Lanes 6 and 8).
To determine the sensitivity of this combined nu-
clease-protection and PCR technique in comparison
with a S; nuclease protection assay alone, a mixing
experiment was performed. FIG. 4 shows S; nuclease
protection analysis of the chimeric bcr/abl transcriptsin
the K562 cell line and two Phi-positive CML patients.
Samples (25 ug) of total cellular RNA were coprecipi-
tated with 32P-labelled anti-K28, anti-L6, and MSL-60











buffer, incubated at 50° C. overnight and treated with
S| nuclease as described in the legend of FIG. 3. The S;
nuclease resistant hybrids were precipitated and sub-
jected to electrophoresis in 8% polyacrylamide gel.
The gel was then dried and autoradiographed. Lane1:
end-labelled molecular weight markers (dx 174, Hae
Ii). Lane 2: the normal RNA treated with S; nuclease
(Bethesda Research Laboratory, Gaithersburg, Md.) at
the concentration of 5 units/ul. Incompletely digested
99 mers and 60 mers (arrow heads) were detected. The
S; nuclease used in Lanes 3-10 wasat 20 units/ul. Lane
3: the normal RNA in which no S; nuclease resistant
hybrids were detected. Lane 4: the total RNA sample
(25 ug) from the K562 cell lines. A strong band of 99
bases in size was demonstrated (arrow). Since the 60
mer was not detected, the 99 bp band should represent
antisense oligomer that was protected by the chimeric
ber/abl transcripts. Multiple faint bands detectedin this
assay were due to partial exonuclease cleavage on the
DNA-RNAduplex by S; nuclease. Lane 5: 2.5 ug of the
K562 RNAin 22.5 ug of the normal RNA. A veryfaint
band of 99 bp in size was barely detected (arrow). Lane
6: 0.25 ug of the K562 RNA in 25 ug of the normal
RNA. No band wasdetectable. Lanes 7 and 8: the pre-
treatment (Lane 7) and remission (Lane 8) blood sam-
ples obtained from Patient A. Lanes 9 and 10:the pre-
treatment (Lane 9) and remission (Lane 10) blood sam-
ples obtained from Patient B. No S; nuclease resistant
hybrids were detected in Lanes 7-10. By means of a S,
nuclease protection assay using radiolabelled anti-K28,
anti-L6 and MSL-60, the presence of the chimeric
ber/abl transcripts could be detected in a sample con-
taining 25 ug of total RNA from the K562 cell line
(FIG. 4, Lane 4). In samples with further dilutions, a
faint and questionable band could barely be detected in
the sample containing 2.5 ug of total RNA from the
K562 cell line and 22.5 ug of the normal RNA (FIG.4,
Lane 5). In contrast, a strong and convincing band
representative of the chimeric ber/abl transcripts could
be detected in a sample containing 0.05 ng of total RNA
from the K562cell line and 5 ug of the normal RNA(i.e
1:100,000 dilution) by the present method combining S,
nuclease protection and PCR (FIG. 3B, Lanes3 and 4).
Sequential follow up studies were also performed in
blood samples obtained from two CMLpatients who
had achieved complete hematologic remission resulting
from recombinant alpha interferon therapy. FIG. 5
shows Southern blot analysis of the genomic DNAs
from the blood samples of patients A and B. High mo-
lecular weight DNAs were digested with restriction
endonuclease-Bglll, fractionated in a 0.8% agarose gel
and transferred onto a nylon filter, which was then
hybridized with a 1.2 kb HindIII-BglII ber probe (On-
cogene Science Inc.). Lane 1: genomic DNA from the
normal lymph node. Lanes 2 and 3: the pretreatment
(Lane 2) and remission (Lane 3) blood samples obtained
from patient A. Lane 4 and5: the pretreatment (Lane 4)
and remission (Lane 5) blood samples obtained from
patient B.
While these two patients were in the chronic phase of
disease, the blood samples obtained were shown to have
Ph! chromosome by karyotyping and clonal ber gene
rearrangement by Southernblot analysis (FIG. 5, Lanes
2 and 4). The chimeric bcr/abl transcripts of these pa-
tients were too low in abundance to be detected by
using 25 ug oftotal cellular RNA and S; nuclease pro-
tection analysis (FIG. 4, Lanes 7 and 9). At the time of
remission, karyotyping showed 100% diploid cells,
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Southern blot analysis showed no ber gene rearrange-
ment (FIG.5, Lanes 3 and 5) and S; nuclease protection
assay showed no chimeric ber/abl transcripts (FIG.4,
Lanes 8 and 10). However, residual chimeric ber/abl
transcripts were detected in both remission samples by
the modified PCR technique of the present invention
(FIG. 3B, Lanes 5 and 6).
Modified PCR technique of the present inventionis a
novel approach for the detection of minimal residual
disease in Ph!-positive CML. This technique provides
the opportunity to detect minimal amounts of aberrant
gene products from neoplastic cells that carry a chro-
mosomal translocation. Since it detects minimal num-
bers of Ph!-positive cells that are not detectable by
other modalities, it may be used to identify a subpopula-
tion of Ph!-positive CML patients in remission, who are
at high risk of relapse. Since it requires only 5 ugoftotal
cellular RNA samples, it represents a simple andpracti-
cal methodforclinical usage. It will also be helpful in
understanding theclinical and biological significance of
minimal residual disease in Ph!-positive CML. Accord-
ingly, such information may be used to design new
therapeutic strategies for neoplastic disease.
The following cited references are incorporated by
reference herein for the observations and methods for
which they wereearlier cited.
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Changes may be madein the operation and arrange-
ment of the various steps and procedures described
herein without departing from the concept and scope of
the invention as defined in the following claims.
Whatis claimedis:
1. A method for detecting the unique aberrant gene
transcripts of a targeted cellular genomic abnormality
in a tissue sample, the method comprisingthe stepsof:
* preparing m-RNAortotal cellular RNA from the
tissue sample;
mixing the m-RNAortotal cellular RNA with at
least one antisense synthetic DNA oligonucleotide
complementaryto the unique RNA sequenceofthe
targeted cellular genomic abnormality, said mixing










RNA heteroduplexes when DNA and RNA com-
plementary strands are present;
adding a control DNA oligomer characterized as
having a base sequenceandsize different from that
of the antisense synthetic DNA oligonucleotide;
treating the mixture with a single strand-specific nu-
clease whereby single stranded RNA andsingle
stranded DNA but not double stranded DNA-
RNAheteroduplexes are hydrolyzed:
deactivating the nuclease and denaturing unhydro-
lyzed heteroduplexes to form a mixture of single
stranded DNA and RNA;
subjecting the single stranded DNAofthe denatured
mixture to at least about 20 rounds of polymerase
chain reaction with at least one first primer com-
plementary to a portion of the 3’ end of the an-
tisense synthetic DNAoligonucleotide, at least one
second primeridentical to a portion ofthe 5’ end of:
the antisense synthetic DNA oligonucleotide, and.
at least two control primers,a first control primer
being complementary to at least a portion of one
end of the 3’ end and a second control primer being
complementaryto atleast a portion of the 5’ end of
the control DNA oligomer, said polymerase chain
reaction resulting in amplimers of unhydrolyzed
synthetic DNAoligonucleotide and DNAoligonu-
cleotides complementary thereto; and
detecting the presence of amplimers comprising nu-
cleotide sequences characteristic of the unique
aberrant gene transcripts of the targeted cellular
genomic abnormality or the complementary syn-
thetic DNA oligonucleotide, said presence being
detected only where complementary m-RNA from
the tissue sample has protected the synthetic an-
tisense DNA oligonucleotide from nuclease diges-
tion and wherein detection of amplimers is quanti-
tatively related to aberrant gene transcripts, pro- .
vided that amplified control DNA oligomeris
absent, as an indication of complete single-strand
nuclease hydrolysis.
2. A method for detecting residual chronic myelo-
genous leukemia cells of a patient in a state of clinical
remission, said cells being characterized as having the
Ph! chromosomecapableof producing unique genomic
transcripts, the method comprising the stepsof:
preparing the total cellular RNA or m-RNA from
blood cells of said patient;
mixing the total cellular RNA or m-RNA with a
synthetic antisense DNA oligonucleotide comple-
mentary to characteristic RNA sequences of the
Ph! chromosome, said mixingfacilitating formation
of double stranded DNA-RNA _heteroduplexes
when DNA and RNA complementarystrands are
present;
adding a control DNA oligomer characterized as
having a base sequenceandsize different from that
of the antisense synthetic DNA oligonucleotide;
treating the mixture with a single-strand-specific nu-
clease to hydrolyze single stranded RNA andsin-
gle stranded DNA but not double stranded DNA-
RNA heteroduplexes;
deactivating the nuclease and denaturing unhydro-
lyzed heteroduplexes to form a mixture of single
stranded DNA and RNA;
subjecting the single stranded DNAof the denatured
mixture to at lest about 20 rounds of polymerase
chain reaction with at least one first primer com-
plementary to a portion of the 3’ end of the an-
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tisense synthetic DNA oligonucleotide and a sec-
ond primer identical. to a portion of the 5’ end of
the antisense synthetic DNA oligonucleotide, and
at least two contro! primers, a first control primer
being complementaryto at least a portion of the 3’
end and a second control primer being complemen-
tary to at least a portion of the 5’ end of the control
DNA oligomer, said polymerase chain reaction
resulting in amplimers of unhydrolyzed synthetic
DNAoligonucleotide and DNA oligonucleotides
complementary thereto; and
detecting the presence of amplimers comprising nu-
cleotide sequences characteristic of unique gene
transcripts of the Philadelphia chromosomeor the
complementary, synthetic DNA oligonucleotide,
said presence being detected only where comple-
mentary m-RNA from the tissue sample has pro-
tected the synthetic DNA oligonucleotide from
nuclease digestion and wherein the presence of
amplimers is quantitatively related to the unique
genomic transcripts derived from the Ph! chromo-
some provided that amplimers generated from the
added control DNA oligomer are absent, as an
indication of complete single-strand nuclease hy-
drolysis.
3. The method of claim 1 or 2 wherein the primers are
oligonucleotides of between about 12 and about 20
nucleotides in length.
4. The method ofclaim 1 or 2 wherein the primers are
oligonucleotides of about 12 nucleotides in length.
5. The method of claim 1 or 2 wherein the first primer
is primer ber Ex III (+) derived from the third exon of
the ber region or ber Ex II (+) derived from the second
exon of the ber region.
6. The method ofclaim 1 or 2 wherein the first primer
is defined further as being a mixture of primer ber ExIII
(+) and primer ber Ex IT (+).
7. The methodofclaim 1 or 2 wherein the first primer
is defined further as being a mixture of two different
primers.
8. The method of claim 1 wherein the second primer
is detined further as being a mixture of two different
primers.
9. The method of claim 1 or 2 wherein the second
primeris primer abl (—) derived from the second exon
of the abl gene.
10. The method of claim 1 or 2 wherein the primers
are at a concentration of about 1 uM.
11. The method of claim 1 or 2 wherein the synthetic
antisense DNA oligonucleotide is from about 60 to
about 150 nucleotides in length.
12. The method of claim 1 or 2 wherein the synthetic
antisense DNA oligonucleotide is about several hun-









13. The method of claim 1 or 2 wherein the synthetic
DNAoligonucleotide comprises sequence antisense to
the L6 mRNAjunction (anti-L6).
14, The method ofclaim 1 or 2 wherein the synthetic
DNAoligonucleotide comprises sequence antisense to
K-28 m-RNA junction (anti-K28).
15. The methodof claim 1 or 2 wherein the synthetic
DNAoligonucleotide comprises anti-L6 and anti-K28.
16. The method of claim 1 wherein the targeted cellu-
lar genomic abnormality is the Philadelphia chromo-
some, Ph!.
17. The method of claim 1 wherein the nuclease is
single-strand-specific nuclease, such as S; nuclease,
Mung bean nuclease or RNase.
18. The method of claim 1 or 2 wherein the detecting
step involves electrophoresis of the polymerase chain
reaction amplimer product.
19. The method ofclaim 1 or 2 wherein the detecting
step involves preparation of a Southern blot.
20. The method of claim 1 or 2 wherein the detecting
step involves electrophoretic separation of amplimers,
transfer to a nylon ornitrocellulose paper and exposure
to a labelled oligonucleotide probe having a nucleotide
sequence characteristic of the unique aberrant gene
transcripts of the chromosomal abnormality or a geno-
mic componentthereof.
21. The method of claim 1 or claim 2 wherein the
control DNA oligomer, except for 12 bases on each of
its ends, is a randomly selected 60-base DNA oligomer
essentially lacking complementarity with the mRNA
derived from genes associated with aberrant gene tran-
scripts.
22. The method of claim 2 wherein the genomic tran-
scripts are chimeric ber/abl transcripts.
23. The method of claim 1 or claim 2 wherein one
control DNAprimeris 18q21(+) complementary to 12
bases of the 3’ end and the other control DNA primeris
J#(—) identical to 12 bases at the 5’ end of the control
DNAoligomer.
24. The method of claim 2 wherein one antisense
synthetic DNA oligonucleotide comprises 99 bases
having a sequence antisense to junction K28 and the
other antisense synthetic DNA oligonucleotide com-
prises 99 bases having a sequence antisense to junction
L6 of the chimeric transcripts characteristic of chronic
myelogenous leukemia.
25. The method of claim 24 wherein both antisense
oligonucleotides include 50 bases from an abl gene sec-
ond exon and 49 bases from a ber gene second orthird
exon, wherein the 50 bases are associated with a 5’ end
and the 49 bases with a 3’ end.
26. The method of claim 1 or 2 wherein the primers
for the antisense synthetic DNA nucleotide are identi-
cal to the primers for the control DNA oligomer.
27. The method of claim 1 or 2 wherein the first
primer and the second primer are between about 12 and
about 20 nucleotides in length.
* * * * *
